Transendothelial migration of leukocytes is promoted by plasma from a subgroup of immune thrombocytopenic purpura patients with small-vessel ischemic brain disease

American Journal of Hematology

Volumn 83, Issue 3, 2008, Pages 206-211

  Jimenez, Joaquin J ^a   Jy, Wenche ^a   Mauro, Lucia M ^a   Horstman, Lawrence L ^a   Fontana, Vincenzo ^a   Ahn, Yeon S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD146 ANTIGEN; CD31 ANTIGEN; DANAZOL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAP JUNCTION PROTEIN; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; NITRIC OXIDE; OCCLUDIN; PHOSPHOLIPID ANTIBODY; THROMBOCYTE ACTIVATING FACTOR; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLEEDING; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CELL STRAIN U937; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LEUKOCYTE MIGRATION; MALE; MONOCYTE; PLASMA; PRIORITY JOURNAL; RISK FACTOR; SPLENECTOMY; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK;

ADULT; AGED; BRAIN ISCHEMIA; CELL MIGRATION ASSAYS, LEUKOCYTE; CELLS, CULTURED; CEREBROVASCULAR CIRCULATION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MICROCIRCULATION; MIDDLE AGED; MONOCYTES; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECURRENCE; REFERENCE VALUES; SPLENECTOMY; U937 CELLS;

EID: 39749108806     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21061     Document Type: Article

References (56)

1. Harrington WJ, Sprague CC, Minnich V, et al. Immunologic mechanisms in idiopathic and neonatal thrombocytopenic purpura. Ann Int Med 1953;38:433-469.
2. McMillan RM, Imbach P. Immune thrombocytopenic purpura. In: Loscalzo J,Schafer AI, editors. Thrombosis and Hemorrhage, 2nd ed. Baltimore: Williams & Wilkins; 1998. pp 643-664.
3. Jy W, Horstman LL, Arce M, Ahn YS. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. J Lab Clin Med 1992;119:334-345.
4. Ahn YS, Horstman LL, Jy W, et al. Vascular dementia in patients with immune thrombocytopenic purpura (ITP). Thromb Res 2002;107:337-344.
5. Horstman LL, Jy W, Jimenez JJ, Ahn YS. Endothelial microparticles as markers of endothelial dysfunction [Review]. Front Biosci 2004;9:1118-1135.
6. Brezinschek RI, Oppenheimer-Marks N, Lipsky PE. Activated T cells acquire endothelial cell surface determinants during transendothelial migration. J Immunol 1999;162:1677-1684.
7. Jimenez JJ, Jy W, Mauro L, et al. Elevated endothelial microparticle-monocyte complexes induced by multiple sclerosis plasma and the inhibitory effects of interferon-β 1b on release of endothelial microparticles, formation and transendothelial migration of monocyte-endothelial microparticle complexes. Mult Scler 2005;11:310-315.
8. Kermode AG, Thompson JA, Tofts PS, et al. Breakdown of the blood-brain-barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis: Pathogenesis and clinical implications. Brain 1990;113:1477-1489.
9. Adams RA, Bauer J, Flick MJ, et al. The fibrin-derived peptide γ (377-395) peptide inhibits microglial activation and suppresses relapsing paralysis in central nervous system autoimmune disorders. J Exp Med 2007;204:571-582.
10. Abbott NJ. Dynamics of CNS barriers: Evolution, differentiation, and modulation. Cell Mol Neurobiol 2005;25:5-21.
11. Kniesel U, Wolberg H: Tight junctions of the blood-brain barrier. Cell Mol Neurobiol 2000;20:57-76.
12. Shusta EV. Blood-brain barrier. In: Aird WC, editor. Endothelial Cells in Health and Disease. New York: Taylor and Francis; 2005. pp 33-63.
13. Bazzoni G: Endothelial tight junctions: Permeable barriers of the vessel wall. Thromb Haemost 2006;95:36-42.
14. Ferrero E, Ferrero ME, Pardi R, Zocchi MR. The platelet endothelial cell adhesion molecule-1 (PECAM 1) contributes to endothelial barrier function. FEBS Lett 1995;374:323-326.
15. Ferrero E, Villa A, Ferrero ME, et al. Tumor necrosis factor alpha-induced vascular leakage involves PECAM1 phosphorylation. Cancer Res 1996 56:3211-3215.
16. Muller WA, Weigl SA, Deng X, Phillips DM. PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med 1993;178:449-460.
17. Liao F, Huynh HK, Eiroa A, et al. Migration of monocytes across endothel um and passage through extracelular matrix involve seperate molecular domains of PECAM-1. J Exp Med 1995;182:1337-1343.
18. Yang L, Froio RM, Sciuto TM, et al. ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-α activated vascular endothelium under flow [with commentary p394]. Blood 2005;106:584-592.
19. Wong D, Prameya R, Dorovini-Zis K. In vitro adhesion and migration of T lymphocytes across monolayers of human brain microvessel endothelial cells: regulation by ICAM-1, VCAM-1, E-selectin and PECAM-1. J Neuropathol Exp Neurol 1999;58:138-152.
20. Bolton SJ, Anthony DC, Berry VH. Loss of the tight junction proteins occludin and zona occludens-1 from cerebral vascular endothelium during neutrophil-induced blood-brain barrier breakdown in vivo. Neuroscience 1998;86:1245-1257.
21. Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability [Review]. Nature 2005;437:497-501.
22. Bardin N, Anfosso F, Massé J-M, et al. Identification of CD146 as a component of the endothelial junction involved in the control of cell-cell adhesion. Blood 2001;98:3677-3684.
23. Bardin N, Moal V, Anfosso F, et al. Soluble CD146, a novel endothelial cells marker, is increased in physiological settings linked to endothelial junctional alterations. Thromb Haemost 2003;90:915-920.
24. Middleton J, Patterson AM, Gardner L, et al. Leukocyte extravisation: Chemokine transport and presentation by the endothelium. Blood 2002;100:3853-3860.
25. Abbott NJ. Inflammatory DUPE SEE 2107 2187. Cell Mol Neurobiol 2000;20:131-147.
26. Benjamin CF, Silva JS, Fortes ZB, et al. Inhibition of leukocyte rolling by nitric oxide during sepsis leads to reduced migration of active microbicidal neutrophils. Infect Immun 2002;70:3602-3610.
27. Kamath AF, Chauhan AK, Dole VS, et al. Elevated levels of homocysteine comprimise blood-brain barrier integrity in mice. Blood 2006;107:591-593.
28. Callea L, Arese M, Orlandini A, et al. Platelet activating factor is elevated in cerebral spinal fluid and plasma of patients with relapsing-remitting multiple sclerosis. J Neuroimmunol 1999;94:212-221.
29. Kihara Y, Ishii S, Kita Y, et al. Dual phase regulation of experimental allergic encephalomyelitis by platelet activating factor. J Exp Med 2005;202:853-863.
30. Iwamoto S, Kawasaki T, Kambayashi J, et al. Platelet microparticles: A carrier of platelet-activating factor? Biochem Biophys Res Com 1996;218:940-944.
31. Mitsios JV, Vini MR Stengel D, et al. Human platelets secrete the plasma type of platelet activating acetylhydrolase primarily associated with microparticles. Arterioscl Thromb Vasc Biol 2006;26:1907-1913.
32. Wakelin MW, Sanz M-J, Dewar A, et al. An anti-platelet-endothelial cell adhesion molecule-1 antibody inhibits leukocyte extravasation from mesenteric microvessels in vivo by blocking the passage through the basement membrane. J Exp Med 1996;184:229-239.
33. Hughes GRV, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1985;13:486-489.
34. Bidot CJ, Jy W, Horstman LL, et al. Antiphospholipid antibodies in immune thrombocytopenic purpura tend to emerge in exacerbation and decline in remission. Br J Haematol 2004;128:366-372.
35. Brey RL, Levine SR, Worth CLS. Neurologic manifestations in the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette JC, et al., editors. The Antiphospholipid Syndrome II: Autoimmune Thrombosis. New York: Elsevier; 2002. pp 155-168.
36. Minagar A, Jy W, Jimenez JJ, et al. Elevated plasma endothelial microparticles in multiple sclerosis. Neurology 2001;56:1319-1324.
37. Sugiyama Y, Yamamoto Y. Characterization of serum anti-phospholipid antibodies in patients with multiple sclerosis. Tohoku J Exp Med 1996;178:203-215.
38. Marchiori PE, DosReis M, Quevedo ME, et al. Cerebrospinal fluid and serum antiphospholipid antibodies in multiple sclerosis, Guillain-Barre syndrome and systemic lupus erythematosus. Ar Qneuropsiquiatr 1990;48:465-468.
39. Bidot CJ, Jy W, Jimenez JJ, et al. Antiphospholipid antibodies in multiple sclerosis are exclusively IgM class, and occur predominately in exacerbations (Abstract). Neurology 2005;64(6 Suppl 1):A194 (Ab no. PQ3.123).
40. Ijdo JW, Conti-Kelly AM, Greco P, et al. Anti-phospholipid antibodies in patients with multiple sclerosis and MS-like illnesses: MS or APS? Lupus 1999;8:109-115.
41. Cuadrado MJ, Khamashta MA, Ballesteros A, et al. Can neurological manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore) 2000;79:57-68.
42. Hughes GRV. The antiphospholipid syndrome and 'multiple sclerosis' [with editorial, pg 109-115]. Lupus 1999;8:89.
43. Sanna G, Bertolaccini ML, Hughes GRV. Hughes syndrome, the antiphospholipid syndrome. A new chapter in neurology. Ann NY Acad Sci 2005;1051:465-486.
44. Meroni PL, Raschi E, Testoni C, et al. Antiphospholipid antibodies and the endothelium. Rheum Dis Clin North Am 2001;27:587-602.
45. Pierangeli SS, Espinola RG, Ferrara DE, Harris EN. Activation of endothelial cell nuclear factor kB by antiphospholipid antibodies. Blood 2001;98:56b (Ab no. 3837).
46. Simantov R, Lo SK, Gharavi A, et al. Antiphospholipid antibodies activate vascular endothelial cells. Lupus 1996;5:440-441.
47. McCrae KR, DeMichele A, Samuels P, et al. Detection of endothelial cell-reactive immunoglobulin in patients with antiphospholipid antibodies. Br J Haematol 1991;79:595-605.
48. Tokita S, Arai M, Yamamoto N, et al. Specific cross reaction of IgG anti-phospholipid antibody with platelet glycoprotein IIIa. Thromb Haemost 1996;75:168-174.
49. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;92:1556-1564.
50. Dorovini-Zis K, Bowman PD, Prameya R. Adhesion and migration of human polymorphonuclear leukocytes across cultured bovine brain microvascular endothelial cells. J Neuropathol Exp Neurol 1992;51:194-205.
51. Nagy Z, Vastag M, Kolev K, et al. Human cerebral microvascular endothelial cell culture as a model system to study the blood-brain interface in ischemic/hypoxic conditions. Cell Mol Neurobiol 2005;25:201-211.
52. Jimenez J, Jy W, Mauro L, et al. Elevated endothelial microparticles in thrombotic thrombocytopenic purpura (TTP): Findings from brain and renal microvascular cell culture and patients with active disease. Br J Haematol 2001;112:81-90.
53. Jimenez JJ, Jy W, Mauro L, et al. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res 2003;109:175-180.
54. Jimenez JJ, Jy W, Mauro LM, et al. Endothelial microparticles released in thrombotic thrombocytopenic purpura express von Willebrand factor and markers of endothelial activation. Br J Haematol 2003;123:896-902.
55. Jy W, Minagar A, Jimenez JJ, et al. Endothelial microparticles (EMP) bind and activate monocytes: Elevated EMP-monocyte complexes in multiple sclerosis. Front Biosci 2004;9:3137-3144.
56. Horstman LL, Jy W, Arce M, Ahn YS. Danazol distribution in plasma and cell membranes as related to altered cell properties: Implications for mechanism. Am J Hematol 1995;50:179-187.